Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 2/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851164 | 0.92 | RAB9A (0.48) | RAB9ANPC1POLBERN1PRKCI | |
| SCHEMBL31338945 | 0.92 | RAB9A (0.48) | RAB9ANPC1POLBERN1PRKCI | |
| SCHEMBL1726296 | 0.83 | DYRK1A (0.48) | RAB9ANPC1POLBERN1PRKCI | |
| SCHEMBL5035088 | 0.79 | CHRM2 (0.58) | RAB9ANPC1POLBERN1DYRK1A | |
| SCHEMBL29833531 | 0.79 | CHRM2 (0.58) | RAB9ANPC1POLBERN1DYRK1A | |
| SCHEMBL32679636 | 0.78 | CHRM2 (0.48) | RAB9ANPC1POLBERN1PRKCI | |
| SCHEMBL10053022 | 0.78 | CHRM2 (0.48) | RAB9ANPC1POLBERN1PRKCI | |
| SCHEMBL27978630 | 0.78 | RAB9A (0.45) | RAB9ANPC1POLBPRKCIDYRK1A | |
| SCHEMBL3642105 | 0.77 | RAB9A (0.44) | RAB9ANPC1POLBERN1PRKCI | |
| SCHEMBL18149084 | 0.76 | RAB9A (0.35) | RAB9ANPC1POLBERN1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221338-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS U.S.A. INC. FOR BARBADOS | 2008-09-11 | — | — | US | claimed |
| EP-1891034-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-02-27 | — | — | EP | claimed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | claimed |
| WO-2007076157-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| US-7442806-B2 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-28 | — | — | US | disclosed |
| US-20080221338-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS U.S.A. INC. FOR BARBADOS | 2008-09-11 | — | — | US | disclosed |
| EP-1891034-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-02-27 | — | — | EP | disclosed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
| WO-2007076157-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221338-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | RAB9A 956/4885NPC1 4114/4885POLB 587/4885 |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | RAB9A 956/4885NPC1 4114/4885POLB 587/4885 |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | RAB9A 956/4885NPC1 4114/4885POLB 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.